Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Receivables (2020 - 2023)

Historic Receivables for Rocket Pharmaceuticals (RCKT) over the last 4 years, with Q4 2023 value amounting to $50000.0.

  • Rocket Pharmaceuticals' Receivables changed N/A to $50000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $50000.0, marking a year-over-year change of. This contributed to the annual value of $50000.0 for FY2023, which is N/A changed from last year.
  • As of Q4 2023, Rocket Pharmaceuticals' Receivables stood at $50000.0.
  • In the past 5 years, Rocket Pharmaceuticals' Receivables registered a high of $1.6 million during Q2 2020, and its lowest value of $50000.0 during Q4 2023.
  • Over the past 4 years, Rocket Pharmaceuticals' median Receivables value was $1.0 million (recorded in 2021), while the average stood at $964285.7.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Receivables tumbled by 3750.0% in 2021, and later tumbled by 1000.0% in 2022.
  • Rocket Pharmaceuticals' Receivables (Quarter) stood at $1.1 million in 2020, then dropped by 9.09% to $1.0 million in 2021, then dropped by 10.0% to $900000.0 in 2022, then crashed by 94.44% to $50000.0 in 2023.
  • Its last three reported values are $50000.0 in Q4 2023, $900000.0 for Q1 2022, and $1.0 million during Q2 2021.